-
Medicare Details Plan to Cover Alzheimer's Treatments
Patients will have to participate in registries that collect real-world data on how the drug works as a condition of coverage.
-
Experimental Drug Slows Worsening Effects of Alzheimer's
Eli Lilly and Co. said Wednesday its experimental Alzheimer’s drug appeared to slow worsening of the mind-robbing disease in a large study. NBC 5’s Bianca Castro talked with Frisco neurologist Dr. Aimee Garza about how it works.
-
Eli Lilly Says Experimental Drug Slows Alzheimer's Worsening
Eli Lilly and Co. says its experimental Alzheimer’s drug appears to slow worsening of the mind-robbing disease after an 18-month trial.
-
Alzheimer's: Medicare Will Cover Leqembi for All Patients If FDA Approves Drug, CMS Chief Says
Medicare has severely restricted access to the medication Leqembi, which costs $26,500 per year, because the FDA approved it just on an expedited basis.
-
Eli Lilly Says Experimental Alzheimer's Drug Reduces Brain Plaque in Early Study
Eli Lilly said a higher dose of the up-and-coming Alzheimer’s treatment remternetug had a larger effect on clearing amyloid plaque.
-
Alzheimer's ‘Escapees': Scientists Seek Clues From Those Who Evade Genetic Fate
Scientists are digging into why a few people escape the rarest form of Alzheimer’s, which is inherited and strikes young. Every so often, someone dodges their family’s genetic fate.
-
Report: Growing Burdens for Alzheimer's Family Caregivers
Inside the numbers of the Alzheimer’s Association’s latest report, and how Connecticut families face caregiving challenges.
-
Why a New Alzheimer's Drug Is Having a Slow US Debut
The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away. Experts say scant coverage of the drug and a long setup time needed by health systems are two main factors behind the slow debut. The U.S. Food and Drug Administration approved Leqembi from Japanese drugmaker Eisai in early...
-
New Alzheimer's Drug Slows Progression of Disease But It Comes With Caveats
A new Alzheimer’s drug is hitting the market with experts voicing a lot of caution.
-
Probe: Alzheimer's Drug Approval ‘Rife With Irregularities'
The Biogen company wanted to set an “unjustifiably high” initial price of $56,000 a year for the Alzheimer’s drug, investigators said.
-
New Services, Technology to Improve At-Home Alzheimer's Care
Assisted Living Services has developed some new services and technology to improve at-home care for people with Alzheimer’s.
-
First CT Support Group for Men Caregivers of Loved Ones With Alzheimer's Launches
November is Alzheimer’s Awareness Month, and it is no secret that caring for someone with that disease is heartbreaking. Now, the first-of-its-kind caregiver support group is launching in Connecticut. It is geared particularly toward men. Pansy Homecare Service is starting virtual group, with support from the Alzheimer’s Association. The first meeting is Tuesday, Nov. 1. Two-thirds of the people...
-
First-Of-Its-Kind Alzheimer's Support Group Launches in Connecticut
A first-of-its-kind Alzheimer’s caregiver group launches in Connecticut this week amid Alzheimer’s Awareness Month.
-
Alzheimer's Treatment Shows Promise in Early Results of Study, Drugmaker Says
Biogen and Japan’s Eisai Co. said early results showed that the treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo after 18 months of the infused treatment
-
Even Simple Exercise May Help Aging Brain, Study Hints
New research hints that even simple exercise just might help seniors with mild memory problems.
-
Filipek Tennis Tournament Raises Money for Alzheimer's Association
More than 400 people participated in the Wint Filipek Tennis Tournament and all proceeds will go to the CT Alzheimer’s Association.
-
Connecticut Whale Set to Host Alzheimer's Awareness Game
The Connecticut Whale will play its first game since Dec. 19 on Saturday, facing off not only against the Metropolitan Riveters but also against Alzheimer’s.
-
Connecticut Whale Set to Host Alzheimer's Awareness Game
The Connecticut Whale will play its first game since Dec. 19 on Saturday, facing off not only against the Metropolitan Riveters but also against Alzheimer’s. The club has partnered with the Connecticut chapter of the Alzheimer’s Association to raise money and awareness for the disease that affects roughly 80,000 people in the state. For some players, this cause is especially...
-
Biogen Cuts the Price Tag on Its Alzheimer's Drug in Half
Biogen is slashing the price of its Alzheimer’s treatment months after the drug debuted to widespread criticism for an initial cost that can reach $56,000 annually